LPL Receptor Inhibitor

LPL Receptor Inhibitors (51):

Cat. No.	Product Name	Effect	Purity

HY-D1005

Poloxamer 407 (F127)	Inhibitor
Poloxamer 407 (F127) is a nonionic surfactant that is 100% active and relatively non-toxic to cells at low concentrations, and frequently used with dye AM esters such as Indo-1 AM, Fura-2 AM, Calcein AM, Fluo-3 AM, Fluo-4 AM, Quest Fluo-8 AM and Quest Rhod-4 AM, etc. to improve their water solubility. Poloxamer 407 is also a lipoprotein lipase inhibitor.

HY-18778B

Obicetrapib potassium	Inhibitor
Obicetrapib (TA-8995; DEZ-001) potassium is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib potassium potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib potassium can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD).

HY-182375A

SLB1122168 free base	Inhibitor
SLB1122168 free base is a Spinster Homolog 2 (Spns2) inhibitor. SLB1122168 free base inhibits Spns2-mediated sphingosine-1-phosphate (S1P) release with an IC₅₀ of 94 nM. SLB1122168 free base induces lymphopenia in circulating lymphocytes in mice and rats.

HY-16040

AM095 free acid	Inhibitor	99.02%
AM095 (free acid) is a potent LPA1 receptor antagonist with IC₅₀ values of 0.98 and 0.73 μM for recombinant human or mouse LPA1 respectively.

HY-149004

SLF1081851	Inhibitor	98.02%
SLF1081851 is a Spns2 inhibitor, inhibits S1P release (IC₅₀=1.93 μM). SLF1081851 plays a key role in development and immune system.

HY-116147

Ceranib-2	Inhibitor	98.92%
Ceranib-2 is a potent and nonlipid ceramidase inhibitor that inhibits cellular ceramidase activity with an IC₅₀ of 28 μM in SKOV3 cells. Ceranib-2 induces the accumulation of multiple ceramide species, decreases levels of sphingosine and sphingosine-1-phosphate (S1P), and induces cell apoptosis. Anticancer activity.

HY-100619A

BMS-986020 sodium	Inhibitor	99.88%
BMS-986020 (AM152) sodium is a high-affinity lysophosphatidic acid receptor 1 (LPA1) antagonist. BMS-986020 sodium inhibits bile acid and phospholipid transporters with IC₅₀s of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively. BMS-986020 sodium has the potential for the treatment of idiopathic pulmonary fibrosis (IPF).

HY-18075

LPA2 antagonist 1	Inhibitor	98.63%
LPA2 antagonist 1 is a LPA2 antagonist with an IC₅₀ of 17 nM.

HY-162655

SLF80821178	Inhibitor	99.70%
SLF80821178 is a potent and orally active inhibitor of Sphingosine-1-Phosphate Transporter (Spns2). SLF80821178 inhibits S1P release with an IC₅₀ of 51 nM in HeLa cells and a T_1/2 of 2.4 h in mouse.

HY-14113

2-Acetyl-4-tetrahydroxybutyl imidazole	Inhibitor	98.06%
2-Acetyl-5-tetrahydroxybutyl imidazole is a potent sphingosine-1-phosphate (S1P) lyase inhibitor in vivo.

HY-126145

S1PR1 modulator 1	Inhibitor	99.52%
S1PR1 modulator 1 is a selective S1PR1 inhibitor, with a pIC₅₀ of 7.6, with >40- and >80-fold selectivity, over the other S1PR isoforms S1PR2/3/4.

HY-P99318

Sonepcizumab	Inhibitor
Sonepcizumab (LT 1009) is a fully human anti-S1P monoclonal antibody. Sonepcizumab has the potential for the research of metastatic renal cell carcinoma (mRCC).

HY-14370

LX2931	Inhibitor	98.88%
LX2931 is an inhibitor of Sphingosine 1-Phosphate Lyase (S1PL). LX2931 works by increasing levels of S1P inside and outside the cell. The decrease in S1PL activity leads to a significant increase in S1P content in tissues, especially in lymphoid tissues which may lead to a restricted exodus of lymphocytes from secondary immune tissues, resulting in lymphocytopenic and immunosuppressive effects in the peripheral circulation. LX2931 can be used in research for the study of autoimmune diseases, especially rheumatoid arthritis.

HY-150254A

SLB1122168 formic	Inhibitor	99.91%
SLB1122168 formic is a Spinster Homolog 2 (Spns2) inhibitor. SLB1122168 formic inhibits Spns2-mediated sphingosine-1-phosphate (S1P) release with an IC₅₀ of 94 nM. SLB1122168 formic induces lymphopenia in circulating lymphocytes in mice and rats.

HY-139094

A6770	Inhibitor	≥99.0%
A6770 is an orally active, potent sphingosine 1-phosphate (S1P) lyase (S1PL) inhibitor. A6770 is phosphorylated and the phosphorylated form directly inhibits S1P lyased.A6770, a potential key metabolite of THI, induces a [³H]dhS1P increase.

HY-158783

SACLAC	Inhibitor	99.70%
SACLAC, a Ceramide analog, is a potent and covalent acid ceramidase (ASAH1; AC) inhibitor with a K_i of 97.1 nM. SACLAC effectively blocks AC activity and induces a decrease in sphingosine 1-phosphate (S1P) and total ceramide levels. SACLAC reduces the levels of splicing factor SF3B1 and alternative Mcl-1 mRNA splicing, increases pro-apoptotic Mcl-1S levels to induce apoptosis in acute myeloid leukemia (AML) cells. SACLAC reduces the leukemic burden in human AML xenograft mouse models.

HY-RS12394

S1PR2 Human Pre-designed siRNA Set A	Inhibitor
S1PR2 Human Pre-designed siRNA Set A contains three designed siRNAs for S1PR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS12391

S1PR1 Human Pre-designed siRNA Set A	Inhibitor
S1PR1 Human Pre-designed siRNA Set A contains three designed siRNAs for S1PR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-150254

SLB1122168	Inhibitor
SLB1122168 is a Spinster Homolog 2 (Spns2) inhibitor. SLB1122168 inhibits Spns2-mediated sphingosine-1-phosphate (S1P) release with an IC₅₀ of 94 nM. SLB1122168 induces lymphopenia in circulating lymphocytes in mice and rats.

HY-115566

S1PL-IN-1	Inhibitor	99.9%
S1PL-IN-31 (compound ) is an oral active sphingosine-1-phosphate (S1P) lyase inhibitor with the IC₅₀ of 210 nM. S1PL-IN-31 is Smoothened receptor antagonist with the IC₅₀ of 440 nM. S1PL-IN-31 can be used for study of experimental autoimmune encephalomyelitis.

Name
Email *

	Sorry, but the email address you supplied was invalid.